US FDA Approves Pirtobrutinib for Untreated CLL/SLL
The US FDA has approved Eli Lilly’s pirtobrutinib (Jaypirca) for previously untreated CLL/SLL in adults without known 17p deletion.
Pirtobrutinib US FDA Approval | 05/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy